Why Indian Drugmakers Are Losing Pricing Power In The US
(MENAFN- Live Mint) Indian drugmakers are losing pricing power in the US, their largest market, as buyer concentration and intensifying competition squeeze sales and margins. In the July-September 2026 quarter, Cipla's North America revenue fell 19% in rupee terms as sales of generic Revlimid, a blood cancer drug, declined amid competition. Revlimid also weighed on Dr. Reddy's North America sales, while Lupin's US sales fell 13% from the April-June quarter after it lost exclusivity on Tolvaptan and Mirabegron.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment